Altimmune

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Altimmune and other ETFs, options, and stocks.

About ALT

Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. 

CEO
Jerome B. Durso
CEOJerome B. Durso
Employees
57
Employees57
Headquarters
Gaithersburg, Maryland
HeadquartersGaithersburg, Maryland
Founded
1997
Founded1997
Employees
57
Employees57

ALT Key Statistics

Market cap
594.12M
Market cap594.12M
Price-Earnings ratio
-3.25
Price-Earnings ratio-3.25
Dividend yield
Dividend yield
Average volume
2.68M
Average volume2.68M
High today
$3.11
High today$3.11
Low today
$3.02
Low today$3.02
Open price
$3.07
Open price$3.07
Volume
2.60M
Volume2.60M
52 Week high
$7.73
52 Week high$7.73
52 Week low
$2.56
52 Week low$2.56

Stock Snapshot

The current Altimmune(ALT) stock price is $3.05, with a market capitalization of 594.12M. The stock trades at a price-to-earnings (P/E) ratio of -3.25.

As of 2026-05-31, Altimmune(ALT) stock has fluctuated between $3.02 and $3.11. The current price stands at $3.05, placing the stock +1.0% above today's low and -1.9% off the high.

Altimmune(ALT) shares are trading with a volume of 2.6M, against a daily average of 2.68M.

During the past year, Altimmune(ALT) stock moved between $2.56 at its lowest and $7.73 at its peak.

During the past year, Altimmune(ALT) stock moved between $2.56 at its lowest and $7.73 at its peak.

ALT News

CNN 3d
symbol__ Stock Quote Price and Forecast - CNN

...

symbol__ Stock Quote Price and Forecast - CNN
TipRanks 3d
Altimmune reports 48-week data from IMPACT Phase 2b trial of pemvidutide

Altimmune (ALT) announced that new 48-week data from the IMPACT Phase 2b trial show that pemvidutide, an investigational balanced glucagon/GLP-1 dual receptor a...

Analyst ratings

80%

of 10 ratings
Buy
80%
Hold
20%
Sell
0%

People also own

Based on the portfolios of people who own ALT. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.